الفهرس 
The Relation between the body mass index and response to neoadjuvant chemotherapy in breast cancer patients
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
Introduction: Breast cancer is the most commonly diagnosed cancer in
females constituting 11.7% of total cancer cases, about 2,261,419 new
cases of breast cancer were diagnosed in 2020 worldwide patients with
locally advanced breast cancer, and some with earlier-stage disease
(particularly if triple negative or human epidermal growth factor receptor
2 [HER2] positive), are treated with neoadjuvant systemic therapy. The
goal of neoadjuvant chemotherapy is to induce a tumor response before
surgery and enable breast conservation, assess responsiveness of the
tumor to chemotherapy and achieving pCR which correlate with
improved survival.
Aim of the Work: Describe the relation between the body mass index
and response to neoadjuvant chemotherapy in breast cancer patients
regarding achieving pCR or less than pCR.
Patients and Methods: This is a retrospective study that included all
female patients with pathologically proven locally advanced non
metastatic breast cancer who received neoadjuvant chemotherapy at the
medical oncology department, NCI, Cairo University in the period
between January 2018 till January 2019.
Results: Our study included 167 patients .The Median weight of the
cases was 80 kg. Median BMI was 33.5 with range between 20.7 and
54.2.Median age was 46 years old, 67.6% were premenopausal, positive
family history was found in 18% of cases, about 44.9% of the patients
were luminal A, 20.9% were TPBS, 23.3% were TNBC and 10.7% were
HER2 enriched. About 26.3% of the patients achieved pCR 88.6% of
them were overweight and obese. The relation between BMI and MIILER
grade was insignificant.
Conclusion: Our study didn’t show a relation between the body mass
index and response to neoadjuvant chemotherapy.